上颌窦内控释制剂对慢性鼻窦炎转归的影响

Influence of controlled-release formulations in maxillary sinus for chronic sinusitis

目的研究红霉素控释制剂植入上颌窦内治疗慢性鼻窦炎的临床疗效。方法在鼻内镜下经下鼻道开窗,将红霉素控释制剂植入上颌窦内。结果 48侧在21 d人体环境下鼻腔分泌物中仍能检测到红霉素,45侧达到临床治愈标准。结论红霉素控释制剂的临床应用可减少或终止口服或静脉用药,减少术后换药次数,减轻患者痛苦,临床疗效可靠。

Objective To study the implantation of controlled release formulations of erythromycin treatment of maxillary sinusitis in clinical efficacy.Methods Controlled-release formulations of erythromycin were implanted in the maxillary sinus by nasal antrostomy of the inferior nasal meatus under endoscopy.Result After 21 days erythromycin was detected in nasal secretions of 48 sides and 45 sides reached standards of clinical cure.Conclusion Clinical application of controlled-release formulations of erythromycin can reduce or stop oral or intravenous drug use,reduce the frequency of postoperative dressing,also reduce the suffering of patients.